Comparative Study of the Mutant Prevention Concentrations of Moxifloxacin, Levofloxacin, and Gemifloxacin against Pneumococci
- 1 February 2010
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (2), 673-677
- https://doi.org/10.1128/aac.01353-09
Abstract
We tested the propensity of three quinolones to select for resistant Streptococcus pneumoniae mutants by determining the mutant prevention concentration (MPC) against 100 clinical strains, some of which harbored mutations in type II topoisomerases. Compared with levofloxacin and gemifloxacin, moxifloxacin had the lowest number of strains with MPCs above the susceptibility breakpoint ( P < 0.001), thus representing a lower selective pressure for proliferation of resistant mutants. Only moxifloxacin gave a 50% MPC (MPC 50 ) value (1 μg/ml) within the susceptible range.This publication has 24 references indexed in Scilit:
- In Vitro Activity of Garenoxacin against Streptococcus pneumoniae Mutants with Characterized Resistance MechanismsAntimicrobial Agents and Chemotherapy, 2009
- Changes in Fluoroquinolone-ResistantStreptococcus pneumoniaafter 7-Valent Conjugate Vaccination, SpainEmerging Infectious Diseases, 2009
- Effect of Protein Binding on the Pharmacological Activity of Highly Bound AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2007
- Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic modelJournal of Antimicrobial Chemotherapy, 2006
- Antipneumococcal Activity of DW-224a, a New Quinolone, Compared to Those of Eight Other AgentsAntimicrobial Agents and Chemotherapy, 2006
- Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory PathogensAntimicrobial Agents and Chemotherapy, 2005
- Mutant Prevention Concentration of Gemifloxacin for Clinical Isolates of Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2003
- Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and LevofloxacinAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of InfectionAntimicrobial Agents and Chemotherapy, 2001